ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.59 USD | -6.50% |
|
-10.69% | -19.31% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,167 | 3,541 | 2,126 | 907.1 | 540.2 | 540.8 | - | - |
| Enterprise Value (EV) 1 | 2,636 | 2,713 | 1,317 | 330.6 | 91.47 | 181.8 | 436.8 | 540.8 |
| P/E ratio | -14.2 x | -12.1 x | -7.89 x | -2.71 x | -1.54 x | -1.61 x | -1.63 x | -1.61 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 55.2 x | 3,733 x | 5,686 x | 571 x | 131 x | 13.1 x |
| EV / Revenue | - | - | 34.2 x | 1,361 x | 963 x | 192 x | 106 x | 13.1 x |
| EV / EBITDA | -13.3 x | -10.8 x | -5.37 x | -1.03 x | -0.29 x | -0.7 x | -1.43 x | -1.57 x |
| EV / FCF | -14 x | -15 x | -6.38 x | -1.46 x | -0.38 x | -0.93 x | -1.98 x | -2.53 x |
| FCF Yield | -7.14% | -6.67% | -15.7% | -68.3% | -262% | -107% | -50.5% | -39.6% |
| Price to Book | 4.17 x | 3.28 x | 2.32 x | 1.36 x | 1.06 x | 1.58 x | 2.29 x | - |
| Nbr of stocks (in thousands) | 121,902 | 140,280 | 142,516 | 144,210 | 168,277 | 208,784 | - | - |
| Reference price 2 | 25.98 | 25.24 | 14.92 | 6.290 | 3.210 | 2.590 | 2.590 | 2.590 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 2/28/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 38.49 | 0.243 | 0.095 | 0.9467 | 4.13 | 41.35 |
| EBITDA 1 | -197.6 | -250.8 | -245.3 | -321.2 | -313.5 | -259.3 | -305 | -343.8 |
| EBIT 1 | -202 | -258.2 | -255.8 | -335.4 | -327.7 | -289.4 | -313.3 | -328.8 |
| Operating Margin | - | - | -664.58% | -138,044.86% | -344,986.32% | -30,565.1% | -7,585.53% | -795.32% |
| Earnings before Tax (EBT) 1 | -184.9 | -250.2 | -257 | -332.6 | -327.3 | -277.9 | -302.5 | -311.9 |
| Net income 1 | -184.6 | -250.2 | -257 | -332.6 | -327.3 | -278.6 | -304.5 | -317.5 |
| Net margin | - | - | -667.74% | -136,885.6% | -344,489.47% | -29,428.86% | -7,371.74% | -767.83% |
| EPS 2 | -1.830 | -2.080 | -1.890 | -2.320 | -2.090 | -1.610 | -1.586 | -1.606 |
| Free Cash Flow 1 | -188.1 | -181.1 | -206.3 | -225.7 | -239.2 | -195 | -220.8 | -214 |
| FCF margin | - | - | -535.89% | -92,884.77% | -251,841.05% | -20,597.65% | -5,344.52% | -517.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 2/28/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.051 | 0.061 | 0.086 | 0.049 | 0.047 | 0.052 | 0.044 | 0.043 | 0.021 | 0.022 | 1.013 | 0.0131 | 0.00693 | 0.0162 | 0.0162 |
| EBITDA 1 | -69.65 | -76.3 | -72.92 | -78.63 | -93.31 | -95.56 | -76.88 | -59.4 | -81.63 | - | -64.88 | -64.45 | -64.05 | -69.14 | -69.06 |
| EBIT 1 | -73.89 | -79.99 | -76.59 | -82.49 | -96.37 | -99.07 | -80.52 | -62.98 | -85.11 | -69.5 | -67.38 | -70.08 | -73.89 | -77.56 | -79.42 |
| Operating Margin | -144,888.24% | -131,134.43% | -89,062.79% | -168,344.9% | -205,051.06% | -190,519.23% | -182,995.45% | -146,453.49% | -405,280.95% | -315,927.27% | -6,650.84% | -533,743.56% | -1,066,220.78% | -479,680.89% | -491,173.78% |
| Earnings before Tax (EBT) 1 | -74.87 | -79.85 | -74.79 | -83.15 | -94.85 | -98.7 | -77.99 | -61.32 | -85.78 | -65 | -64.7 | -67.6 | -69.95 | -74.94 | -76.83 |
| Net income 1 | -74.87 | -79.85 | -74.79 | -83.15 | -94.85 | -98.7 | -77.99 | -61.32 | -85.78 | -65 | -65.27 | -68.14 | -70.55 | -74.94 | -76.83 |
| Net margin | -146,800% | -130,901.64% | -86,961.63% | -169,689.8% | -201,802.13% | -189,815.38% | -177,247.73% | -142,593.02% | -408,466.67% | -295,454.55% | -6,441.93% | -518,950.19% | -1,018,093.8% | -463,473.1% | -475,151.52% |
| EPS 2 | -0.5400 | -0.5600 | -0.5200 | -0.5800 | -0.6600 | -0.6800 | -0.5300 | -0.3700 | -0.5100 | -0.3800 | -0.3554 | -0.3576 | -0.3682 | -0.3833 | -0.3767 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/4/22 | 8/9/22 | 11/2/22 | 2/28/23 | 5/3/23 | 8/2/23 | 11/2/23 | 3/14/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 531 | 828 | 809 | 576 | 449 | 359 | 104 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -188 | -181 | -206 | -226 | -239 | -195 | -221 | -214 |
| ROE (net income / shareholders' equity) | -27.7% | -29.3% | -25.8% | -42% | -55.5% | -99.5% | -96.6% | - |
| ROA (Net income/ Total Assets) | -24.8% | -25.7% | -22.7% | -35.8% | -44.7% | -68.9% | -77.5% | - |
| Assets 1 | 745.8 | 972.8 | 1,133 | 927.9 | 732.2 | 404.4 | 392.9 | - |
| Book Value Per Share 2 | 6.220 | 7.690 | 6.430 | 4.610 | 3.040 | 1.640 | 1.130 | - |
| Cash Flow per Share | - | -0.9600 | -1.360 | -1.540 | - | - | - | - |
| Capex 1 | 50.8 | 66 | 21.4 | 5.19 | 1.52 | 0.75 | 2.31 | 5.03 |
| Capex / Sales | - | - | 55.72% | 2,136.21% | 1,595.79% | 79.22% | 55.89% | 12.17% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/23/22 | 2/28/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
2.59
USD
Average target price
11.34
USD
Spread / Average Target
+337.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.31% | 541M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.20% | 21.6B | |
| -12.38% | 22.31B | |
| -6.59% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- ALLO Stock
- Financials Allogene Therapeutics, Inc.